Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
Biohaven Pharmaceutical has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Biohaven Pharmaceutical's investors include RA Capital Management, Connecticut Innovations, Vivo Capital, Venrock, OUP (Osage University Partners).
Biohaven Pharmaceutical is headquartered in New Haven, United States.
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
Biohaven Pharmaceutical is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biohaven Pharmaceutical — Funding & Investors." VCBacked, November 12, 2025, https://www.vcbacked.co/company/biohaven-pharmaceutical. Accessed July 19, 2026.
VCBacked. (2025). Biohaven Pharmaceutical — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/biohaven-pharmaceutical
{{cite web |title=Biohaven Pharmaceutical — Funding & Investors |url=https://www.vcbacked.co/company/biohaven-pharmaceutical |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated